Clinical and Translational Oncology

, Volume 8, Issue 1, pp 15–21

Mediterranean diet, olive oil and cancer

  • Ramón Colomer
  • Javier A. Menéndez


Olive oil is an integral ingredient of the «Mediterranean diet» and accumulating evidence suggests that it may have a potential role in lowering the risk of several types of cancers. The mechanisms by which the carcer-preventing effects of olive oil can be performed, however, are not known. We recently hypothesized that a novel molecular explanation concerning the anti-cancer actions of olive oil may relate to the ability of its monounsaturated fatty acid (MUFA) oleic acid (OA; 18:1n-9) to specifically regulate cancer-related oncogenes. Supporting our hypothesis, exogenous suplementation of cultured breast cancer cells with physiological concentrations of OA was found to suppress the overexpression of HER2 (Her-2/neu,erB-2), a well-characterized oncogene playing a key role in the etiology, progression and response to chemotherapy and endocrine therapy in approximately 20% of breast carcinomas. OA treatment was also found to synergistically enhance the efficacy of trastuzumab, a humanized monoclonal antibody binding with high affinity to the ectodomain (ECD) of the Her2-coded p185HER2 oncoprotein. Moreover, OA exposure significantly diminished the proteolytic cleavage of the ECD of HER2 and, consequently, its activation status, a crucial molecular event that determines both the aggressive behavior and theresponse to trastuzumab of Her2-overexpressing breast carcinomas. Our most recent findings further reveal that OA exposure may suppresses HER2 at the transcriptional level by up-regulating the expression of theEts protein PEA3-a DNA-binding protein that specifically blocks HER2 promoter activity-in breast, ovarian and stomach cancer cell lines. This anti-HER2 property of OA offers a previously ously unrecognized molecular mechanism by which olive oil may regulate the malignant behavior of cancer cells. From a clinical perspective, it could provide an effective means of influencing the outcome of Her-2/neu-overexpressing human carcinomas with poor prognosis. Indeed, OA-induced transcriptional pression of HER2 oncogene may represent a novel genomic explanation linking «Mediterranean diet», olive oil and cancer as it seems to equally operate in various types of Her-2/neu-related carcinomas.

Key words

olive oil oleic acid Her 2 erbB-2 mediterranean diet cancer 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Byers T. What can randomized controlled trials tell us about nutrition and cancer prevention?. Ca Cancer J Clin. 1999;49:555–61.CrossRefGoogle Scholar
  2. 2.
    Martinez-González MA, Estruch R. Medilerranean diet, antioxidants and cancer: the need for randomized trials. Cancer Prevention. 2004;13:327–35.CrossRefGoogle Scholar
  3. 3.
    Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer. 1997;33:1075–107.PubMedCrossRefGoogle Scholar
  4. 4.
    Trichopoulou A, Costacou T, Bamia C, Trichopoulos D. A dherence to a Mediteranean diet and survival in a Greek population. N Engl J Med. 2005;26;348(26):2599–608.Google Scholar
  5. 5.
    Alarcón de la Lastra C, Barranco MD, Motilva, V, Herrerías JM. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des. 2001;7:933–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Generaliat de Catalunya, Department de Sanitat i Seguretat Social. Avaluació de l'estat nutricional de la població catalana (1992–93) Avaluació dels hàbits alimentaris, el consum d'aliments, energia i nutri ents, i de l'estat nutricional mitjançant indicadors bioquímics i antropomètrics.Google Scholar
  7. 7.
    Dirección General de Salud Pública y Participación. Consejería de Salud. Junta de Andalucía Valoración del Estado nutricional de la Comunidad Autónoma de Andalucía (2000). Informe sobre consumo de alimentos.Google Scholar
  8. 8.
    Donaldson MS. Nutrition and cancer: A review of the evidence for an anti-cancer diet. Nutritional Journal. 2004;5:19.Google Scholar
  9. 9.
    Demark-Wahnefried W, Rock CL. Nutrition-related issues for the breast cancer survivor. Semin Oncol. 2005;30:789–98.CrossRefGoogle Scholar
  10. 10.
    Quiles JL, Huertas JR, Battino M, Mataix J, Ramírez Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology. 2002.Google Scholar
  11. 11.
    Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr. Cancer Therap. 2004;3:294–300.CrossRefGoogle Scholar
  12. 12.
    Shacter E, Williams JA, Hinson RM, Senturker S, Lee Y-J. Oxidative stress interferes with cancer chemotherapy: inhibition of lymphoma cell apoptosis and phagocytosis. Blood. 2000;96:307–13.PubMedGoogle Scholar
  13. 13.
    Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Rad Biol Med. 2000; 29:323–33.PubMedCrossRefGoogle Scholar
  14. 14.
    Lange BJ, Gerbing RB, Feusner J, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.PubMedCrossRefGoogle Scholar
  15. 15.
    Calle EE, Rodriguez KC, Walker-Thurmond K, Thun MJ. Overweight, obesity and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRefGoogle Scholar
  16. 16.
    Meyerhardt JA, Catalano PJ, Haller DG, et al. Influence of body mass index on outcomes and treatment-related toxicity in patients with colon carcinoma. Cancer. 2003;98:484–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Sanderson IR, Naik S. Dietary regulation of intestinal gene expression. Annu Rev Nutr. 2000;20:311–38.PubMedCrossRefGoogle Scholar
  18. 18.
    Wahle KW, Rotondo D, Heys SD. Polyunsaturated fatty acids and gene expression in mammalian systems. Proc. Nutr Soc. 2003;62(2):349–60.PubMedCrossRefGoogle Scholar
  19. 19.
    Menéndez JA, Vellón L, Colomer R, Lupu R. Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses Her 2/neu (erbB-2) expression and synergistically enhances the growth inhibitoryeffects of transtuzumab (HerceptinTM) in breast cancer cells with Her-2/neu oncogene amplification. Ann Oncol. 2005;16 (3):359–71.PubMedCrossRefGoogle Scholar
  20. 20.
    Jump BD. Fatty acid regulation of gene transcription. Critical Reviews in Clinical Laboratory Sciences. 2004;41(1):41–78.PubMedCrossRefGoogle Scholar
  21. 21.
    Gosmain Y, Dif N, Berbe V, et al. Regulation of SREBP-1 expression and transcriptional action on HKII and FAS genes during fasting and refeeding in rat tissues J Lipid Res. 2005.Google Scholar
  22. 22.
    Pégorier JP, Le May C, Girard J. Control of gene expression by fatty acids. The Journal of Nutrition. 2004;134(9):2444S-9S.PubMedGoogle Scholar
  23. 23.
    Hardman WE. (n-3) fatty acids and cancer therapy. J Nutr. 2004;134:3427S-30.PubMedGoogle Scholar
  24. 24.
    Menéndez JA, del Mar Barbacid M, Montero S, et al. Effects of gamma-linolenic acid and oleic on paclitaxel cytotoxicity in human breast cancer cells. Eur J Cancer. 2001;37(3):402–13.PubMedCrossRefGoogle Scholar
  25. 25.
    Menéndez JA, Ropero S, Lupu R, Colomer R. Omega-6 polyunsaturated fatty acid gamma-linolenic acid (18:3n-6) enhances docetaxel (Taxotere) cytotoxicity in human breast carcinoma cells: Relationship to lipid peroxidation and HER-2/neu expression. Oncol Rep. 2004;11(6):1241–52.PubMedGoogle Scholar
  26. 26.
    Menéndez JA, Vellón L, ColomerR, Lupu R. Effect of?-Linolenic Acid on the Transcriptional Activity of the Her-2/neu (erbB-2) Oncogene. J Natl Cancer Inst. 2005; 97(21):1611–5.PubMedCrossRefGoogle Scholar
  27. 27.
    Menéndez JA, Ropero S, del Barbacid MM, et al. Synergistic interaction between vinorelbine and gamma-linoleinic acid in breast cancer cells. Breast Cancer Res. Treat. 2002;72(3):203–19.PubMedCrossRefGoogle Scholar
  28. 28.
    Hughes-Fulford M, Chen Y, Tjandrawinata RR. Fatty acid regulates gene expression and growth of human prostate cancer PC.5 cells. Carcinogenesis 2001;22:701–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Bartoli R, Fernández F, Navarro E, et al. Effect of olive oil on early and late events of colon carcinogenesis in rats: modulation of arachidonic acid metabolism and local prostaglandin E(2) sintesis. Gut. 2000;46:191–9.PubMedCrossRefGoogle Scholar
  30. 30.
    Siddiqui RA, Jenski LJ, Neff K, Harvey K, Kovacs RJ, Stillwell W. Docosahexaenoic acid induces apoptosis in Jurkat cells by a protein phosphatese mediated process. Biochim Biophys Acta. 2001;1499:265–75.PubMedCrossRefGoogle Scholar
  31. 31.
    Martin-Moreno JM, Willett P, Gorgojo L, et al. Dietary fat, olive oil intake and breast cancer risk. Int J Cancer. 1994;58: 774–80.PubMedCrossRefGoogle Scholar
  32. 32.
    Landa MC, Frago N, Tres A. Diet and risk of breast cancer in Spain. Eur J Cancer Prev. 1994;3:313–20.PubMedCrossRefGoogle Scholar
  33. 33.
    Trichopoulou A, Katsouyanni K, Stuver S, et al. Consumption of olive oil and specific food groups in relation to breast cancer risk in Greece. J Natl Cancer Inst. 1995; 87:110–6.PubMedCrossRefGoogle Scholar
  34. 34.
    La Vecchia C, Negri E, Franceshi S, et al. Olive oil, other dietary fats, and the risk of breast cancer. Cancer Causes Control. 1995;6:545–50.PubMedCrossRefGoogle Scholar
  35. 35.
    Simonsen NR, Fernández-Crehuet NJ, Martin-Moreno JM, et al. Tissue stores of individual monounsaturated fatty acids and breast cancer: the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. Am J Clin Nutr. 1998; 68:134–41.PubMedGoogle Scholar
  36. 36.
    Stoneham M, Goldacre M, Seagroatt V, et al. Olive oil, diet and colorectal cancer: an ecological study and a hypothesis. J Epidemiol Community Health. 2000;54:756–60.PubMedCrossRefGoogle Scholar
  37. 37.
    Braga C, La Vecchia C, Franceschi S, et al. Olive oil, other seasoning fats, and the risk of colorectal carcinoma. Cancer 1998; 82:448–53.PubMedCrossRefGoogle Scholar
  38. 38.
    Tzonou A, Hsieh C, Polychronopoulou A, et al. Diet and ovarian cancer: a case-control study in Greece. Int J Cancer. 1993;55:411–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Tzonou A, Lipworth L, Kalandidi A, et al. Dietary factors and the risk of endometrial cancer: a case-control study in Greece. Br J Cancer. 1996;73:1284–90.PubMedGoogle Scholar
  40. 40.
    Zamora-Ardoy MA, Banez Sánchez F, Banez Sánchez C, Alaminos García P. Olive oil: influence and benefits on some pathologies. An Med Interna. 2004;21:138–42.PubMedGoogle Scholar
  41. 41.
    Martin-Moreno JM. The role of olive oil in lowering cancer risk: is the real gold or simply pinchbeck?. J Epidemiol Community Health. 2000;54:726–7.PubMedCrossRefGoogle Scholar
  42. 42.
    Menéndez JA, Ropero S, Lupu R, Colomer R. Dietary fatty acids regulate the activation status of Her-2/neu (c-erbB-2) oncogene in breast cancers cells. Ann Oncol. 2004;15:1719–21.PubMedCrossRefGoogle Scholar
  43. 43.
    Yamamoto T, Ikawa S, Akiyama T, et al. Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature. 1986;319:230–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Bargmann CI, Hung M-C, Weinberg RA. The neu oncogene encodes an epidernal growth factor receptor-related protein. Nature. 1986;319:226–30PubMedCrossRefGoogle Scholar
  45. 45.
    Daly RJ. Take your partners, please-signal diversification by the erbB family of receptor tyrosine kinases. Growth Factors. 1999;16:255–63.PubMedCrossRefGoogle Scholar
  46. 46.
    Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127–37.PubMedCrossRefGoogle Scholar
  47. 47.
    Slamon DJ, Clark GM, Wong SG, et al. Human breat cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 233:177–82.CrossRefGoogle Scholar
  48. 48.
    Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and overian cancer. Science. 1989;244:707–12.PubMedCrossRefGoogle Scholar
  49. 49.
    Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–28.PubMedCrossRefGoogle Scholar
  50. 50.
    Di Fiore PP, Pierce JH, Kraus MH, et al. erB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 1987; 237:178–82.PubMedCrossRefGoogle Scholar
  51. 51.
    Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA. 1987; 84:7159–63.PubMedCrossRefGoogle Scholar
  52. 52.
    Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer Res. 1997;57:1199–205.PubMedGoogle Scholar
  53. 53.
    Eccles SA. The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia. 2001;6:393–406.PubMedCrossRefGoogle Scholar
  54. 54.
    Yu D, Hung MC. Role of erbB2 in breast cancer chemosensitivity. Bioessays. 2000; 22:675–80.CrossRefGoogle Scholar
  55. 55.
    Dowsett M. Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocrinol. Relat. Cancer. 2001;8:191–5.CrossRefGoogle Scholar
  56. 56.
    Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc. Natl Acad Sci USA. 1992;89:4295–9.CrossRefGoogle Scholar
  57. 57.
    Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–44.PubMedGoogle Scholar
  58. 58.
    Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonat antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.PubMedGoogle Scholar
  59. 59.
    Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20:719–26.PubMedCrossRefGoogle Scholar
  60. 60.
    Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–92.PubMedCrossRefGoogle Scholar
  61. 61.
    Nagata Y, Lan KH, Zhou X, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts transtuzumab resistance in patients. Cancer Cell. 2004;6:117–27.PubMedCrossRefGoogle Scholar
  62. 62.
    Miller KD. The role of ErbB inhibitors in trastuzumab resistance. Oncologist. 2004; 9 Suppl 3:16–9.PubMedCrossRefGoogle Scholar
  63. 63.
    Yakes FM, Chinratanalab W, Ritter CA, et al. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 2002;62:4132–41.PubMedGoogle Scholar
  64. 64.
    Carney WP, Neumann R, Lipton A, et al. Potential clinical utility of serum HER-2/neu oncoprotein concentration in patients with breast cancer. Clin Chem. 2003;49:1579–98.PubMedCrossRefGoogle Scholar
  65. 65.
    Hudelist G, Kostler WJ, Attems J, et al. Her-2/neu-triggered intracellular tyrosine kinase activation:in vivo relevance of lig-and-independent activation mechanisms and impact upon the efficacy of trastuzumab-based treatment. Br J Cancer. 2003; 89:983–91.PubMedCrossRefGoogle Scholar
  66. 66.
    Marchetti P. Natural medicine: a ‘new frontier” in oncology? Ann Oncol. 2005;16:339–40.PubMedCrossRefGoogle Scholar
  67. 67.
    Nelson R. Oleic acid suppresses overexpression of ER BB2 oncogene. Lancet Oncol. 2005;6:69.PubMedCrossRefGoogle Scholar
  68. 68.
    Xing X, Wang SC, Xia W, et al. The ets protein PEA5 suppresses HER-2/new overexpression and inhibits tumorigenesis. Nat. Med. 2000;6:189–95.PubMedCrossRefGoogle Scholar
  69. 69.
    Wang SC, Hung MC. Transcriptional targeting of the HER-2/neu oncogene. Drugs Today (Barc). 2000;36:835–43.Google Scholar
  70. 70.
    Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-1 receptor signaling and resistance to transtuzumab (Herceptin). J Natl Cancer Inst. 2001; 93:1852–7.PubMedCrossRefGoogle Scholar

Copyright information

© FESEO 2006

Authors and Affiliations

  • Ramón Colomer
    • 1
  • Javier A. Menéndez
    • 2
    • 3
    • 4
  1. 1.Medical Oncology. Institut Catala d'OncologiaHospital de Girona Dr. Josep TruetaGironaSpain
  2. 2.Department of MedicineEvanston Northwestern Healthcare Research InstituteEvanstonUSA
  3. 3.Department of MedicineNorthwestern University Feinberg School of MedicineChicagoUSA
  4. 4.Robert H. Lurie Comprehensive Cancer Center of Northwestern UniversityChicagoUSA

Personalised recommendations